BDRX

Biodexa Pharmaceuticals plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies that target multiple hallmarks of cancer through a single drug candidate. Headquartered in Cardiff, Wales, Biodexa is advancing a pipeline of small molecule therapeutics designed to attack cancer through dual mechanisms of action, potentially providing superior efficacy compared to single-target therapies. The company's lead programs target both cancer cell metabolism and the tumor microenvironment, representing a next-generation approach to oncology drug development. Biodexa's lead candidate is MTX110, a soluble nano-particle formulation of panobinostat being developed for diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric brain tumor with no effective treatments and universally fatal prognosis. MTX110 is designed to be delivered directly to the tumor via convection-enhanced delivery, potentially achieving higher local drug concentrations while reducing systemic exposure and side effects. The company has received orphan drug designation and rare pediatric disease designation from the FDA, which could provide regulatory and commercial advantages. The company's pipeline includes additional candidates targeting other difficult-to-treat cancers with significant unmet needs. Biodexa's dual mechanism approach aims to simultaneously disrupt cancer cell survival pathways and modify the tumor microenvironment that supports cancer growth and metastasis. The company is conducting clinical trials to evaluate safety, tolerability, and preliminary efficacy of its candidates. Biodexa addresses pediatric and adult cancers where new therapeutic options are desperately needed. The company continues to advance its development programs toward potential regulatory approvals and commercialization while exploring strategic partnerships and additional indications for its technology platform.